The cystic fibrosis care model is evolving to support people living longer with CF and their increasingly diverse health needs. Catalyzed by the approval of Trikafta® and the COVID-19 pandemic, this adaptive and personalized care model encompasses novel ways to connect clinicians and patients.
Site Search
Showing 21 - 24 of 24 results
News
|
Aug. 9, 2022
|
4 min read
The law signals major improvements in health care affordability for people with CF.
News
|
Aug. 23, 2022
|
3 min read
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
News
|
Sept. 1, 2022
|
3 min read
Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.
News
|
Sept. 2, 2022
|
3 min read